Helsinn's First HalfSales Rise 34%
Swiss pharmaceutical firm Helsinn Healthcare SA says first-half 1996 consolidated net sales reached 60.6 million Swiss francs ($48.3 million), a rise of some 34% over the like, 1995 period, and it forecasts turnover in excess of 110 million francs for the full year.
Nimesulide, the company's leading pharmaceutical product, was responsible for part of this progress. It was launched in Ireland (by Helsinn Birex) and in Peru (through Schering Plough) during the past year, and in Belgium (Therabel), India (Elder) and Israel (Rafa) in 1996.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze